FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2674418042> ?p ?o ?g. }

• W2674418042 endingPage "1812" @default.
• W2674418042 startingPage "1802" @default.
• W2674418042 abstract "Neublastin (BG00010) is a first-in-class, glial cell-derived neurotrophic factor shown in preclinical studies and an early clinical trial to have potential for the treatment of neuropathic pain. SPRINT was a phase 2, multicenter, double-blinded, placebo-controlled study to evaluate efficacy/safety of 5 neublastin doses (50, 150, 400, 800, and 1200 μg/kg) administered as an intravenous injection 3 times/week for 1 week in patients with chronic painful lumbosacral radiculopathy, utilizing Bayesian response-adaptive study design. Primary endpoint was change from baseline in mean 24-hour average general pain intensity over a 5-day period (week 1) after the last dose, analyzed using a Bayesian normal dynamic linear model. One hundred seventy-six patients were randomized and received treatment (placebo n = 48, 50 μg/kg n = 38, 150 μg/kg n = 13, 400 μg/kg n = 16, 800 μg/kg n = 20, 1200 μg/kg n = 41). Among the tested neublastin doses, the lowest dose (50 μg/kg) showed the greatest difference from placebo for change from baseline in mean average general pain intensity at week 1 after last dose, followed by the highest dose (1200 μg/kg) (posterior mean difference -1.36 [95% credible interval -2.22 to -0.52] and -0.75 [-1.59 to 0.08], respectively). Similar trends were observed in secondary efficacy endpoints. The most common adverse event in all neublastin dose groups was pruritus (79% vs 10% with placebo). There was no dose-response relationship with respect to primary/secondary efficacy outcomes or incidence of pruritus, despite dose-proportional increases in serum neublastin concentrations. In conclusion, while this study showed some evidence of pain relief with neublastin, particularly at the lowest dose, there was no clear dose-response relationship for pain reduction or the most common adverse event of pruritus." @default.
• W2674418042 created "2017-06-30" @default.
• W2674418042 creator A5001265546 @default.
• W2674418042 creator A5006746410 @default.
• W2674418042 creator A5022689469 @default.
• W2674418042 creator A5030127076 @default.
• W2674418042 creator A5044344264 @default.
• W2674418042 date "2017-06-21" @default.
• W2674418042 modified "2023-10-13" @default.
• W2674418042 title "Safety and efficacy of neublastin in painful lumbosacral radiculopathy: a randomized, double-blinded, placebo-controlled phase 2 trial using Bayesian adaptive design (the SPRINT trial)" @default.
• W2674418042 cites W1571002776 @default.
• W2674418042 cites W1967550266 @default.
• W2674418042 cites W1971208141 @default.
• W2674418042 cites W1987032458 @default.
• W2674418042 cites W1990014844 @default.
• W2674418042 cites W2005540257 @default.
• W2674418042 cites W2005888273 @default.
• W2674418042 cites W2023285758 @default.
• W2674418042 cites W2023777589 @default.
• W2674418042 cites W2029662381 @default.
• W2674418042 cites W2034858091 @default.
• W2674418042 cites W2041609060 @default.
• W2674418042 cites W2042486840 @default.
• W2674418042 cites W2042810701 @default.
• W2674418042 cites W2043286125 @default.
• W2674418042 cites W2054841134 @default.
• W2674418042 cites W2058950159 @default.
• W2674418042 cites W2069724916 @default.
• W2674418042 cites W2078990683 @default.
• W2674418042 cites W2094310013 @default.
• W2674418042 cites W2096286605 @default.
• W2674418042 cites W2119752070 @default.
• W2674418042 cites W2120758082 @default.
• W2674418042 cites W2128412489 @default.
• W2674418042 cites W2131830199 @default.
• W2674418042 cites W2148083007 @default.
• W2674418042 cites W2154693681 @default.
• W2674418042 cites W2155412494 @default.
• W2674418042 cites W2162878610 @default.
• W2674418042 cites W216700183 @default.
• W2674418042 cites W2171516791 @default.
• W2674418042 cites W2302551128 @default.
• W2674418042 cites W3194956376 @default.
• W2674418042 cites W4238371955 @default.
• W2674418042 cites W83873011 @default.
• W2674418042 doi "https://doi.org/10.1097/j.pain.0000000000000983" @default.
• W2674418042 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5761750" @default.
• W2674418042 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28746076" @default.
• W2674418042 hasPublicationYear "2017" @default.
• W2674418042 type Work @default.
• W2674418042 sameAs 2674418042 @default.
• W2674418042 citedByCount "22" @default.
• W2674418042 countsByYear W26744180422018 @default.
• W2674418042 countsByYear W26744180422019 @default.
• W2674418042 countsByYear W26744180422020 @default.
• W2674418042 countsByYear W26744180422021 @default.
• W2674418042 countsByYear W26744180422022 @default.
• W2674418042 countsByYear W26744180422023 @default.
• W2674418042 crossrefType "journal-article" @default.
• W2674418042 hasAuthorship W2674418042A5001265546 @default.
• W2674418042 hasAuthorship W2674418042A5006746410 @default.
• W2674418042 hasAuthorship W2674418042A5022689469 @default.
• W2674418042 hasAuthorship W2674418042A5030127076 @default.
• W2674418042 hasAuthorship W2674418042A5044344264 @default.
• W2674418042 hasBestOaLocation W26744180422 @default.
• W2674418042 hasConcept C126322002 @default.
• W2674418042 hasConcept C142724271 @default.
• W2674418042 hasConcept C168563851 @default.
• W2674418042 hasConcept C197934379 @default.
• W2674418042 hasConcept C203092338 @default.
• W2674418042 hasConcept C204787440 @default.
• W2674418042 hasConcept C27081682 @default.
• W2674418042 hasConcept C42219234 @default.
• W2674418042 hasConcept C71924100 @default.
• W2674418042 hasConceptScore W2674418042C126322002 @default.
• W2674418042 hasConceptScore W2674418042C142724271 @default.
• W2674418042 hasConceptScore W2674418042C168563851 @default.
• W2674418042 hasConceptScore W2674418042C197934379 @default.
• W2674418042 hasConceptScore W2674418042C203092338 @default.
• W2674418042 hasConceptScore W2674418042C204787440 @default.
• W2674418042 hasConceptScore W2674418042C27081682 @default.
• W2674418042 hasConceptScore W2674418042C42219234 @default.
• W2674418042 hasConceptScore W2674418042C71924100 @default.
• W2674418042 hasIssue "9" @default.
• W2674418042 hasLocation W26744180421 @default.
• W2674418042 hasLocation W26744180422 @default.
• W2674418042 hasLocation W26744180423 @default.
• W2674418042 hasLocation W26744180424 @default.
• W2674418042 hasOpenAccess W2674418042 @default.
• W2674418042 hasPrimaryLocation W26744180421 @default.
• W2674418042 hasRelatedWork W1859326399 @default.
• W2674418042 hasRelatedWork W1966127473 @default.
• W2674418042 hasRelatedWork W1974781192 @default.
• W2674418042 hasRelatedWork W1992458659 @default.
• W2674418042 hasRelatedWork W2074965717 @default.
• W2674418042 hasRelatedWork W2085650940 @default.
• W2674418042 hasRelatedWork W2085830368 @default.
• W2674418042 hasRelatedWork W2119160676 @default.

• next